A Defined Biomatrix Model for Human Vascular Studies

用于人类血管研究的明确生物基质模型

• 批准号: 6527518
• 负责人: RAJ K. SINGH
• 金额: $ 20万
• 依托单位: DIVERSIFIED SCIENTIFIC, INC.
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-05-01 至 2004-09-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6527518
• 关键词: amnion; angiogenesis; artificial membranes; bioassay; biological models; cell cell interaction; cell differentiation; cell migration; cell proliferation; extracellular matrix; extracellular matrix proteins; growth factor; human tissue; model design /development; synthetic peptide; tissue /cell culture; vascular endothelium

DESCRIPTION (provided by applicant): In our initial application we successfully argued for the need to develop a novel human biomatrix model system to examine in vitro the neovascularization process in humans. The overall goal was and is to develop and commercialize the new human bioassay system employing defined Amgel matrices. This human biomatrix exhibits many advantages over existing models. Amgel's unique physiologic properties allowed one to generate matrix environment with defined or controllable bioactivity. Phase I work definitely established that the 3-D Amgel system simulate discrete human vascular cell functions in vitro. We propose two extended tasks in this second Phase to fully accomplish our R&D objectives. They are: 1. To establish efficient protocols for Amgel production, biomatrix analysis and formulation at commercial scale using advanced automated technologies; and 2. To complete the development of the defined human biomatrix systems and validate the practical applications of final products for vascular biology research As evident from our progress, this marketable human biomatrix will be useful for: I) evaluating the mitogenic, motogenic and differentiation responses of human cell/tissue derived factors; 2) examining the potential regulators of early to late neovascularization events; and 3) rapid screening of pro- and anti-angiogenic agents. New artificial vessel system also allows one to examine cell-matrix interactions under both physiologic and pathologic conditions. Thus, there is significant potential for the commercialization of our human biomatrix system for use in biomedical and pharmaceutical research. PROPOSED COMMERCIAL APPLICATION: No acceptable commercial bioassay system for angiogenesis, vasculogenesis currently exists which utilizes a defined human biomatrix. We will develop, optimize and evaluate both reusable and disposable bioassay systems. Sale of proprietary Amgel and pre-packed assay systems would have a world-wide market, both as a research and diagnoostic tool, in the hundreds of thousands of dollars in first 2-3 years. This will impact the fields of wound healing, tissue engineering and vascular diseases.

描述（由申请人提供）：在我们的初始申请中，我们成功 主张需要开发一种新型的人类Biomatrix模型系统来检查 在体外，人类的新血管化过程。总体目标是并且是 开发和商业化新的人类生物测定系统采用定义的 Amgel矩阵。这个人类Biomatrix比现有的许多优势 型号。 Amgel的独特生理特性允许一个人生成矩阵 具有定义或可控制的生物活性的环境。我的工作绝对工作 确定3-D AMGEL系统模拟了离散的人血管细胞 体外功能。我们在第二阶段提出了两个扩展任务，以完全 实现我们的研发目标。他们是： 1。为了建立AMGEL生产的有效协议，Biomatrix分析 并使用先进的自动化技术以商业规模进行配方；和 2。完成定义的人类Biomatrix系统的开发和 验证最终产品用于血管生物学的实际应用 研究 从我们的进度可以明显看出，这种可销售的人类Biomatrix将很有用 对于：i）评估有丝分裂，动作和分化反应的 人类细胞/组织衍生因子； 2）检查 早期至晚期新生血管化事件； 3）迅速筛选亲和 抗血管生成剂。新的人造血管系统还允许人们检查 在生理和病理状况下的细胞玛尔t质相互作用。 因此，我们人类的商业化具有巨大的潜力 用于生物医学和药物研究的Biomatrix系统。 拟议的商业应用： 目前存在使用定义的人类生物机构的血管生成可接受的商业生物测定系统。我们将开发，优化和评估可重复使用和一次性生物测定系统。在最初的2 - 3年中，出售专有AMGEL和预包装的测定系统将在全球范围内作为研究和诊断工具。这将影响伤口愈合，组织工程和血管疾病的领域。